Clinical Trials Logo
  1. Home
  2. Esophagogastric Cancer
  3. NCT04757363

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Esophagogastric Cancer Clinical Trial

Official title:
A Phase II Study of Nivolumab in Combination With FOLFOX and Regorafenib in Patients With HER2-Negative Metastatic Esophagogastric Cancer

Clinical Trial Summary

The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer. Nivolumab is an antibody, like the proteins made by the immune system to protect the body from harm. Nivolumab blocks the protein PD-1 (programmed cell death receptor-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them. FOLFOX is a combination of three standard chemotherapy drugs (leucovorin, 5-fluorouracil, and oxaliplatin) commonly used to treat your type of cancer. The drugs work by damaging the DNA in cancer cells, which can cause the cells to stop growing and die. Regorafenib is a type of drug called a tyrosine kinase inhibitor (TKI). This drug targets the tyrosine kinase protein found in or on the surface of cancer cells that the cells need to survive and grow. Blocking this protein may stop cancer cells from growing, or cause them to grow more slowly or to shrink. The study researchers think that combining nivolumab, FOLFOX, and regorafenib may be a more effective treatment for HER2-negative metastatic esophagogastric cancer than the usual chemotherapy treatment(s) alone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04757363
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 11, 2021
Completion date February 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Recruiting NCT05612048 - A Study of Tooth Erosion in People With Esophagogastric Cancer N/A
Completed NCT04161781 - A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
Completed NCT01803282 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05796102 - PET-MRI Esophagus Feasibility Study N/A
Recruiting NCT04656041 - Folfox+Irinotecan+Chemort In Esophageal Cancer Phase 2
Withdrawn NCT02296671 - Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers Phase 2
Completed NCT02023996 - PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer N/A
Recruiting NCT05117931 - A Study of Amivantamab in People With Esophagogastric Cancer Phase 2
Not yet recruiting NCT03760289 - DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer Phase 2
Completed NCT01167114 - STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer Phase 2
Active, not recruiting NCT03133650 - A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing Phase 1